Evidence map›Paper›PMID 29739850›Full record

ArticleThe Journal of biological chemistry2018

Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease.

J Morgan Knight, Pijus Mandal, Pietro Morlacchi, Garbo Mak, Evan Li, Matthew Madison, Cameron Landers, Brandon Saxton, Ed Felix, Brian Gilbert and 6 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The new era of add-on asthma treatments: where do we stand?Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022
    Review
  8. Review
  9. STAT6 Blockade AbrogatesFrontiers in immunology · 2022
    Article
  10. Article
  11. The immune response to airway mycosis.Current opinion in microbiology · 2021
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 3 countries.

J Morgan KnightFrom the Departments of Medicine, JMK@bcm.edu.
Pijus Mandalthe Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Pietro Morlacchithe Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Garbo MakFrom the Departments of Medicine.
Evan LiFrom the Departments of Medicine.
Matthew Madisonthe Translational Biology and Molecular Medicine Program, and.
Cameron Landersthe Translational Biology and Molecular Medicine Program, and.
Brandon SaxtonMolecular Virology and Microbiology.
Ed Felixthe Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Brian GilbertMolecular Virology and Microbiology.
Joel Sederstromthe Flow Cytometry Core Facility, Baylor College of Medicine, Houston, Texas.
Atul VaradhacharyFannin Innovation Studio and Atrapos Therapeutics, LLC, Houston, Texas 77027.
Melissa M SinghFannin Innovation Studio and Atrapos Therapeutics, LLC, Houston, Texas 77027.
Dev ChatterjeeFannin Innovation Studio and Atrapos Therapeutics, LLC, Houston, Texas 77027.
David B CorryFrom the Departments of Medicine, dcorry@bcm.edu.ORCID 0000-0001-9729-1016
John S McMurraythe Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USMichael E. DeBakey VA Medical Center · US

Funding

Th1 and Th17 Mediators in Experimental EmphysemaR01HL117181 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI CORRY, DAVID B, KHERADMAND, FARRAH · 2013 to 2016
$1.5M
STAT Inhibitors for Asthma TherapyR41AI125007 · NIAID · ATRAPOS THERAPEUTICS, LLC · PI CORRY, DAVID B · 2016 to 2016
$228k
Carbon Black Induced Activation of Lung APCsI01BX002221 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI CORRY, DAVID B · 2013 to 2016
–
BLRD VA I01 BX001673BLRD VA I01 BX002221NHLBI NIH HHS R01 HL117181NIAID NIH HHS R41 AI125007
6 · The paper itself

Abstract

Asthma is a chronic inflammatory disease of the lungs and airways and one of the most burdensome of all chronic maladies. Previous studies have established that expression of experimental and human asthma requires the IL-4/IL-13/IL-4 receptor α (IL-4Rα) signaling pathway, which activates the transcription factor STAT6. However, no small molecules targeting this important pathway are currently in clinical development. To this end, using a preclinical asthma model, we sought to develop and test a small-molecule inhibitor of the Src homology 2 domains in mouse and human STAT6. We previously developed multiple peptidomimetic compounds on the basis of blocking the docking site of STAT6 to IL-4Rα and phosphorylation of Tyr

Indexed as

Molecular Targeted TherapyAnimalsAsthmaCell LineDrug Evaluation, PreclinicalFemaleHumansLungMiceSmall Molecule Librariessrc Homology DomainsSTAT5 Transcription FactorSTAT6 Transcription FactorStructure-Activity RelationshipSmall Molecule LibrariesSTAT5 Transcription FactorSTAT6 Transcription FactorallergenasthmacytokinefungipeptidomimeticSH2 domainSTAT5STAT6STAT transcription factor

Identifiers

PMID29739850
PMCPMC6028980
OpenAlexW2800754367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.